Glucocorticoid resistance in inflammatory bowel disease.
about
Vaccination of the immunocompromised childCurrent stage in inflammatory bowel disease: What is next?Budesonide Multi-matrix for the Treatment of Patients with Ulcerative ColitisMicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseasesPharmacogenetics in inflammatory bowel diseaseGlucocorticoid-dependent hippocampal transcriptome in male rats: pathway-specific alterations with agingChronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-κb pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis miceMultidrug resistance 1 gene polymorphisms may determine Crohn's disease behavior in patients from Rio de Janeiro.Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients.Novel genetic markers in inflammatory bowel disease.Glucocorticosteroids: current and future directions.Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acidBiomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.The glucocorticoid receptor: a revisited target for toxinsCorticosteroid therapy in ulcerative colitis: Clinical response and predictors.Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis.The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis.Crucial steps in the natural history of inflammatory bowel disease.Clinical, serological and genetic predictors of inflammatory bowel disease course.Molecular and cellular mechanisms of pulmonary fibrosis.Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiologyDetection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control.Emerging actions of the nuclear receptor LRH-1 in the gut.IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids.Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapyGenetic variants associated with Crohn's diseaseDissecting asthma pathogenesis through study of patterns of cellular traffic indicative of molecular switches operative in inflammation.Treatment of steroid-naive ulcerative colitis.Budesonide for Crohn's disease.Pharmacogenomics in the treatment of inflammatory bowel disease.Current trends in the diagnosis and treatment of autoimmune hepatitis in Japan.History of and current issues affecting surgery for pediatric ulcerative colitis.Alcoholic hepatitis: diagnosis and management in 2012.Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells.Systemic glucocorticoids: important issues and practical guidelines for the dermatologist.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.The impact of genetic factors on response to glucocorticoids therapy in IBD.Diminishing Effectiveness of Long-Term Maintenance Topical Steroid Therapy in PPI Non-Responsive Eosinophilic Esophagitis.Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Budesonide for the treatment of ulcerative colitis.
P2860
Q22305944-5ABBF43C-BFD1-4C40-BB76-B6E7B1765BECQ26777429-2E46FB00-9ECE-4F2C-B560-ECE7C7C976BDQ26779042-897F5797-F4F1-49D0-8BA6-A789F0BBCE70Q27011618-F0B86A8B-E02C-4C07-8790-B37CA1417954Q28246002-D872C742-5675-47FD-AF6D-EE5D56B0BE07Q28385751-F6B0F5C3-B4BE-412C-AB12-D023EA006B9DQ28608251-E5239D60-241C-4BC2-84CF-EF0FB8291CC6Q33574823-3A166012-0C43-4229-BCDB-78A4F39255D3Q34073595-3A31A8B8-B034-49B3-B89D-B1E60942F004Q34233119-5326EF52-A684-4BFA-B35C-F26910192355Q34903070-54AE8955-5DA6-44A4-9FA1-254DF16D4319Q35011055-B6CBF0E8-7FB5-4BDB-922F-4C510BAF04B8Q35155756-4192D73E-2FA5-4F82-8955-8501652977A3Q35155828-F549D589-AE91-4CF3-8FDB-76BF9EE0652FQ35169366-9D50BB50-FECE-40E1-83A3-1CFF5C253560Q35645531-5C353231-C9CD-4B9E-BD19-60642C8E9ED0Q36132386-0B8531DA-6740-4336-B281-31C4A057F414Q36144457-E1CF0D70-BB3B-45D9-82EF-D54553970786Q36144470-A5FD5A35-C14B-46D7-9866-7B4BD2BC5073Q36237168-9D71CB35-330A-4331-96A0-AE2FCBF7E4BDQ36245600-2ACBE0E1-EEEB-4EA3-A32D-5252FA491853Q36409293-86FEFC82-FE9D-462C-8B1A-B940D5E254D7Q36742648-D7DB7DE3-D1F8-4A48-9334-01EC2C7CB18FQ36916386-B272E8EE-0EE6-48D8-823F-00C086358F8FQ37062611-6EA1515B-F9D8-4783-A3C7-083F17194A18Q37074271-CCBC897C-2904-4939-BB01-004C5B837D4FQ37122082-407B8AF6-4706-46C9-B9BB-756D6D8732DFQ37483916-1186858E-F996-4AB6-922D-7049A9B2B6F9Q37554383-F73CAD10-8E37-45B0-B12F-864A17829033Q37710516-3A2D3840-FF6D-46B5-94A4-7B1564C2AA99Q37951701-7303E713-B153-4620-B642-AA9884FE467EQ38064356-EB5BAFD7-E8BB-4366-94E6-9C97D5D49C6BQ38067131-F7D8A515-5971-4015-95C2-BBD9DC4F1E33Q38308601-7793C733-5ACC-49F0-B21A-9420A89D9C37Q38356324-9B6644AB-72C5-4A4E-8A80-D2C12DA8DC67Q38501680-44EC05B6-EB4E-4F62-B72F-C57BFC6C20DDQ38699711-98D7E1EF-AE73-43E7-9154-0CE5C7F8555DQ38724547-47EC85F5-F7C0-4CED-B3B9-9C0849960908Q38735146-65444BF4-2154-4574-8D4E-E91B1C8066A8Q38828972-82D99BE7-D443-4A86-ABC3-29630575335A
P2860
Glucocorticoid resistance in inflammatory bowel disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Glucocorticoid resistance in inflammatory bowel disease.
@ast
Glucocorticoid resistance in inflammatory bowel disease.
@en
type
label
Glucocorticoid resistance in inflammatory bowel disease.
@ast
Glucocorticoid resistance in inflammatory bowel disease.
@en
prefLabel
Glucocorticoid resistance in inflammatory bowel disease.
@ast
Glucocorticoid resistance in inflammatory bowel disease.
@en
P356
P1476
Glucocorticoid resistance in inflammatory bowel disease.
@en
P2093
Farrell RJ
Kelleher D
P304
P356
10.1677/JOE.0.1780339
P407
P577
2003-09-01T00:00:00Z